A flow-injection chemiluminescence ( FI-CL ) reaction system with diperiodatoargentateⅢ was developed for the determination of hydrocortisone in human serum. The weak chemiluminescence signal from the reaction between DPA and sulfuric acid system can be greatly enhanced in the presence of hydrocortisone. The optimal conditions of the CL system were 1. 0 mol/L H2SO4, 2. 5×10-4 mol/L diperiodatoargentateⅢ, and flow rate of 4. 20 mL/min. Under the optimal conditions, the CL intensity was linearly to the concentration of hydrocortisone from 3 . 0 × 10-10 g/mL to 1 . 0 × 10-7 g/mL and the detection limit was 2 . 2 × 10-10 g/mL ( 3σ) . The relative standard deviation ( RSD ) was 0 . 6% ( n =11 ) for 5 . 0 × 10-8 g/mL hydrocortisone solution. The proposed method was successfully applied to the direct determination of hydrocortisone in serum samples with the recoveries of 93 . 0%-110 . 0%, and the relative standard deviations were 0 . 3%-3 . 2%. The possible chemiluminescence mechanism was investigated by measuring fluorescence spectra and UV-vis absorption spectra of the system.

A novel flow-injection chemiluminescence (FI-CL) method free of CL reagent was developed for the determination of captopril based on its enhancing effect on the CL derived from diperiodatoargentate(III)-sulfuric acid system. Compared with the conventional CL system, the CL system based on trivalent silver was characterized of good selectivity for the absence of CL reagent. The CL mechanism was discussed through CL spectra and UV–vis absorption spectra. The conditions of the FI-CL system were investigated and optimized. Under the optimal conditions, the relative CL intensity was linear with the captopril concentration in the range of 0.3–15.0 μg/mL. The detection limit for captopril was 0.05 μg/mL, and the relative standard deviation (n=11) was 2.0% for 5.0 μg/mL captopril. The proposed method was applied to the analysis of captopril in tablet and human urine with the recoveries of 83.1%–112.5%, and the relative standard deviations of 0.5%–4.4%. The results obtained by the proposed method agreed well with those obtained from HPLC method. The proposed method is fast, convenient, and cost-effective for the determination of captopril in medicine and biological samples.

OBJECTIVETo observe the efficacy and safety of oral cordarone dir reversing persistent atrial fibrillation (AF). METHODS; Eighty-two symptomatic chronic AF out-patients without history of acute diseases or severe hepatic/thyroid dysfunction were given oral cordarone at the loading dose of 200 mg thrice a day for 1-4 weeks followed by a twice-daily administration for another 1-4 weeks, with the maintenance dose of 200 or 100 mg once a day. The incidence of stroke and cardiac events and the mortality rate were compared between 43 patients with restored rhythm on cordarone and 39 patients on digoxin and/or betaloc for ventricular rhythm control.

RESULTSAmong the 82 patients, sinus rhythm restoration was achieved in 43, with a successful rate of 52%. In 18 patients, the ejection fraction increased from (32+/-8)% to (46+/-10)%, left atrium diameter decreased from (4.6+/-1.1) cm to (4.1+/-0.8) cm. Except for slight T4 increase, QT prolongation and bradycardia in 3 cases, severe side effects were not observed in this study. Only one patient with restored sinus rhythm required rehospitalization after half a year for worsened heart failure, but in patients with controlled ventricular rhythm, 1 developed stroke, 1 experienced heart attack and 1 died of heart failure with bleeding.

CONCLUSIONFor patients with symptomatic reversible persistent AF, active treatment with cordarone can be convenient, effective and safe for sinus rhythm restoration.

Adult ; Aged ; Amiodarone ; adverse effects ; therapeutic use ; Anti-Arrhythmia Agents ; adverse effects ; therapeutic use ; Atrial Fibrillation ; drug therapy ; Female ; Humans ; Male ; Middle Aged